Related Experiment Video
Updated: Oct 10, 2025
10:28
The Encapsulation of Cell-free Transcription and Translation Machinery in Vesicles for the Construction of Cellular Mimics
Published on: October 21, 2013
15.3K
Elucidating design principles for engineering cell-derived vesicles to inhibit SARS-CoV-2 infection
Taylor F Gunnels1,2, Devin M Stranford2,3, Roxana E Mitrut2,3
1Department of Biomedical Engineering, Northwestern University, Evanston, IL 60208, USA.
Biorxiv : the Preprint Server for Biology
|December 15, 2021
Summary
Cell-mimicking decoy nanoparticles show potent antiviral efficacy against SARS-CoV-2 variants. This research guides the design of novel nanoparticle therapeutics to combat drug-resistant viral infections.
Area of Science:
- Biotechnology
- Nanomedicine
- Virology
Background:
- Pathogen drug resistance is a critical global health issue.
- SARS-CoV-2 variants pose challenges to existing antibody and vaccine therapies.
- Decoy nanoparticles offer a promising therapeutic strategy against resistant viruses.
Approach:
- Systematically evaluated biologically-derived nanoscale vesicles as decoy nanoparticles.
- Investigated performance across various manufacturing methods and vesicle subclasses.
- Assessed inhibition of multiple model SARS-CoV-2 virions, including antibody-resistant variants.
Key Points:
- Biologically-derived nanoparticles demonstrate potent antiviral efficacy.
- Efficacy is consistent across different manufacturing processes and vesicle types.
- These nanoparticles effectively neutralize SARS-CoV-2 variants resistant to monoclonal antibodies.
- Performance is influenced by virus-decoy binding affinities.
Conclusions:
- Cell-mimicking vesicles provide a foundation for designing effective decoy nanoparticle inhibitors.
- This approach holds potential for treating SARS-CoV-2 and other viral infections.
- Further research can optimize nanoparticle design for enhanced therapeutic outcomes.
